Loading…
Niagen Bioscience presented at the Southwest IDEAS Conference, describing itself as a cash-generating bioscience firm built on nicotinamide riboside. Management cited an FDA reversal on NMN legality and a failed Parkinson's trial as headwinds.
This is a company-specific nutraceutical story with no effect on feed commodity supply or prices.
Not enough comparable past events yet for a historical read.
Moves of each commodity's benchmark from the last close before the event. Historical reads pool past events of the same kind; they describe what happened, not what will. Not investment advice.